Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089752 | 0.81 | PKM (0.68) | PKMPOLBHSD11B1HTR6ALDH1A1 | |
| SCHEMBL617793 | 0.80 | TP53 (0.47) | GUSBHSD17B10PKMPOLBALDH1A1 | |
| SCHEMBL31428550 | 0.77 | HSD17B10 (0.57) | HSD17B10PKMPOLBALDH1A1LMNA | |
| SCHEMBL615233 | 0.76 | SLC40A1 (0.51) | PKMPOLBHSD11B1ALDH1A1LMNA | |
| SCHEMBL617881 | 0.74 | LMNA (0.62) | PKMPOLBHSD11B1ALDH1A1LMNA | |
| SCHEMBL3874145 | 0.74 | FABP4 (0.56) | POLBHTR6LMNATP53 | |
| SCHEMBL10089753 | 0.73 | ALDH1A1 (0.61) | PKMPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10089740 | 0.73 | ALDH1A1 (0.47) | GUSBHSD17B10PKMPOLBHSD11B1 | |
| SCHEMBL28770666 | 0.72 | ALDH1A1 (0.58) | PKMPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL614790 | 0.72 | PKM (0.56) | PKMPOLBHSD11B1HTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | GUSB 2588/4885HSD17B10 33/4885PKM 2539/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | GUSB 4037/4885HSD17B10 1003/4885PKM 3481/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | GUSB 4037/4885HSD17B10 1003/4885PKM 3481/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | GUSB 2858/4885HSD17B10 874/4885PKM 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.